Influenza A virus vaccine H7N9 - sanofi pasteur

Drug Profile

Influenza A virus vaccine H7N9 - sanofi pasteur

Alternative Names: 2017 H7N9 IIV; A/H7N9 virus vaccine

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H7N9 subtype

Most Recent Events

  • 20 Feb 2018 Phase-II clinical trials in Influenza-A virus H7N9 subtype (In volunteers, Prevention, Adjuvant therapy) in USA (IM) (NCT03318315)
  • 14 Feb 2018 Phase-II clinical trials in Influenza-A virus H7N9 subtype (Prevention, In adults, In the elderly, In volunteers) in USA (IM) (NCT03312231)
  • 26 Oct 2017 National Institute of Allergy and Infectious diseases plans a phase II trial for Influenza (Prevention) in USA in December 2017 (NCT03318315)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top